Generic Name: cobimetinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Genentech

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Cotellic is a kinase inhibitor approved to treat inoperable or metastatic melanoma with BRAF V600E or V600K mutations in combination with Zelboraf (vemurafenib).

General Info

Cotellic is a targeted therapy that interferes with the activity of MEK (mitogen-activated extracellular signal-regulated kinase) proteins that play a role in cell growth. It is more effective when combined with the BRAF inhibitor Zelboraf. Certain BRAF gene mutations, including V600E and V600K, promote tumor growth.

A clinical trial showed that Cotellic plus Zelboraf delayed progression of melanoma in people with BRAF V600 mutations more than Zelboraf alone. Cotellic was first approved in 2015.


Dosing Info:

Cotellic is a once-daily pill that can be taken with or without food.

Side Effects

Common adverse reactions include diarrhea, nausea, vomiting, fever, photosensitivity reactions and elevated liver enzymes. More serious adverse events may include new malignancies, heavy bleeding, heart problems, severe skin reactions, eye problems, liver toxicity and muscle damage. Cotellic can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: August 9, 2020